Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Is Finding PD-L1 Testing Is Helping Keytruda

Executive Summary

Merck & Co. Inc. is heartened by market data showing about 70% of lung cancer patients who test positive for the PD-L1 biomarker are placed on Keytruda therapy, which could turn into an advantage as the PD-1 inhibitors move into the first-line setting.


Related Content

Does CheckMate 026 Take Bristol Out Of The End Game?
Merck Defends Its Offensive Strategy For Keytruda
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
Brandicourt Not Ready To Raise Medivation Bid Just Yet
Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts